Table 1.
Selected characteristics of the study participants
| Naive GPA | Active GPA | Inactive GPA | Control | |
|---|---|---|---|---|
| n | 4 | 10 | 11 | 10 |
| Age (mean ± s.d.) | 52·6 ± 10·9 | 49·7 ± 12·6 | 48·1 ± 13·4 | 50·7 ± 12·6 |
| Gender (female/male) | 3/1 | 5/5 | 5/6 | 4/6 |
| BVAS (min–max) | 14–24 | 6–28 | 0 | 0 |
| GC treatment (yes/no) | 0/4 | 4/6 | 6/5 | – |
| GC dose (mg/day) (min–max) | 0 | 10–20 | 4–8 | – |
| cANCA (RU/ml) (min–max) | 64–156 | 37–200 | <20–140 | <20 |
| CRP (mg/ml) | 108 ± 82·6 | 20 ± 14 | 5·8 ± 3·8 | <5·0 |
| PBMC (103/µl) | 13·9 ± 7·4 | 10·5 ± 4·3* | 7·03 ± 2·74 | 5·4 ± 2 |
| PMN (103/µl) | 11·6 ± 7·3 | 5·9 ± 5·4* | 4·73 ± 3 | 2·83 ± 1·5 |
| PLT (103/µl) | 416·7 ± 155·6 | 294·5 ± 102·3* | 235 ± 80 | 207 ± 45·7 |
| Procalcitonine (ng/ml) | <0·05 | <0·05 | <0·05 | <0·05 |
| Creatinine (µmol/l) | 230·3 ± 62 | 103 ± 79 | 136·2 ± 110 | 99 ± 24 |
| LDH (U/Ll) | 645 ± 250 | 505 ± 149·5* | 512·5 ± 128* | 370 ± 52 |
Naive GPA = patients with newly diagnosed not treated GPA; active GPA = patients with BVAS>2; inactive GPA = patients with BVAS = 0; BVAS = Birmingham Vasculitis Activity Score
*
P < 0·05, in comparison with controls; GC = glucocorticosteroids.